CA2777664C - Macrocyclic integrase inhibitors - Google Patents
Macrocyclic integrase inhibitors Download PDFInfo
- Publication number
- CA2777664C CA2777664C CA2777664A CA2777664A CA2777664C CA 2777664 C CA2777664 C CA 2777664C CA 2777664 A CA2777664 A CA 2777664A CA 2777664 A CA2777664 A CA 2777664A CA 2777664 C CA2777664 C CA 2777664C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- methyl
- naphthyridine
- mixture
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09172853 | 2009-10-13 | ||
| EP09172853.5 | 2009-10-13 | ||
| PCT/EP2010/065300 WO2011045330A1 (en) | 2009-10-13 | 2010-10-13 | Macrocyclic integrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2777664A1 CA2777664A1 (en) | 2011-04-21 |
| CA2777664C true CA2777664C (en) | 2014-06-10 |
Family
ID=41720665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2777664A Active CA2777664C (en) | 2009-10-13 | 2010-10-13 | Macrocyclic integrase inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8497270B2 (https=) |
| EP (1) | EP2488521B1 (https=) |
| JP (1) | JP5624148B2 (https=) |
| KR (1) | KR20120087916A (https=) |
| CN (1) | CN102574854B (https=) |
| AU (1) | AU2010305805B2 (https=) |
| BR (1) | BR112012008586A2 (https=) |
| CA (1) | CA2777664C (https=) |
| EA (1) | EA019558B1 (https=) |
| ES (1) | ES2446720T3 (https=) |
| IL (1) | IL218845A0 (https=) |
| MX (1) | MX2012004426A (https=) |
| NZ (1) | NZ598766A (https=) |
| WO (1) | WO2011045330A1 (https=) |
| ZA (1) | ZA201202516B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2487176A1 (en) * | 2011-02-14 | 2012-08-15 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus |
| WO2014008636A1 (en) * | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| EP2931730B1 (en) | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
| EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| AU2014267951A1 (en) | 2013-05-17 | 2015-11-19 | Merck Sharp & Dohme Corp. | Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| MD4794B1 (ro) | 2013-09-27 | 2022-02-28 | Merck Sharp & Dohme Corp | Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV |
| PL3636649T3 (pl) | 2014-01-24 | 2024-05-06 | Turning Point Therapeutics, Inc. | Diaryle makrocykliczne jako modulatory kinaz białkowych |
| WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| JP6917974B2 (ja) | 2015-07-06 | 2021-08-11 | ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ジアリール大環状多形 |
| FI3733187T3 (fi) | 2015-07-21 | 2024-12-18 | Turning Point Therapeutics Inc | Kiraalinen diaryylimakrosykli ja sen käyttö syövän hoidossa |
| US10548910B2 (en) | 2015-11-17 | 2020-02-04 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors |
| WO2017106071A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
| WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| US10934312B2 (en) | 2016-12-02 | 2021-03-02 | Merck Sharp & Dohme Corp. | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| US11286264B2 (en) | 2017-07-28 | 2022-03-29 | Turning Point Therapeutics, Inc. | Macrocyclic compounds and uses thereof |
| LT3728271T (lt) | 2017-12-19 | 2022-12-12 | Turning Point Therapeutics, Inc. | Makrocikliniai junginiai, skirti ligų gydymui |
| WO2020197991A1 (en) | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| IL295677B1 (en) | 2020-02-24 | 2026-04-01 | Gilead Sciences Inc | Tetracyclic compounds for the treatment of HIV infection |
| CA3192145A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| CN112358477A (zh) * | 2020-11-10 | 2021-02-12 | 牡丹江医学院 | 一种用于治疗胆囊炎的药物及其制备方法 |
| FI4196479T3 (fi) | 2021-01-19 | 2024-01-17 | Gilead Sciences Inc | Substituoituja pyridotriatsiiniyhdisteitä ja niiden käyttöjä |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| CN115974886A (zh) * | 2022-11-22 | 2023-04-18 | 国科大杭州高等研究院 | 一种含有二氢苯并呋喃骨架的大环内酰胺化合物及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS210880B1 (cs) | 1979-10-19 | 1982-01-29 | Jiri Krepelka | Substituované imidy kyselin 4-arylnaftalen-2,3-dikarboxylových |
| CS225002B1 (cs) | 1980-12-12 | 1984-02-13 | Krepelka Jiri | Deriváty 9-fenyl-1H-benzo/f/isoindol-1,3-dionu a způsob jejich výroby |
| JPH04217684A (ja) | 1990-05-30 | 1992-08-07 | Shionogi & Co Ltd | アルド−ス還元酵素阻害物質 |
| WO1996008478A1 (en) * | 1994-09-13 | 1996-03-21 | Kyowa Hakko Kogyo Co., Ltd. | Anti-hiv drug |
| US6919351B2 (en) | 2000-10-12 | 2005-07-19 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors |
| CA2425440C (en) * | 2000-10-12 | 2010-04-13 | Merck & Co., Inc. | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| JP2004517860A (ja) | 2000-10-12 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
| JP2004513134A (ja) | 2000-10-12 | 2004-04-30 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類 |
| US20040157804A1 (en) | 2002-10-16 | 2004-08-12 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| EP2161258A3 (en) | 2002-11-20 | 2010-04-07 | Japan Tabacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| EP1578748B1 (en) | 2002-12-27 | 2010-09-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| US6890942B2 (en) | 2003-05-16 | 2005-05-10 | Bristol-Myers Squibb Company | Acyl sulfonamides as inhibitors of HIV integrase |
| US20070185007A1 (en) | 2003-09-19 | 2007-08-09 | Haolun Jin | Aza-quinolinol phosphonate integrase inhibitor compounds |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US8129385B2 (en) | 2005-04-28 | 2012-03-06 | Shionogi & Co., Ltd. | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| US20080214527A1 (en) * | 2005-08-04 | 2008-09-04 | Takashi Kawasuji | Hiv Integrase Inhibitors |
| EA200801144A1 (ru) * | 2005-10-27 | 2008-10-30 | Сионоги Энд Ко., Лтд. | Полициклическое карбамоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич |
| US8039458B2 (en) * | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200811153A (en) | 2006-06-23 | 2008-03-01 | Japan Tobacco Inc | 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| EP2283024B1 (en) * | 2008-03-10 | 2013-05-15 | Janssen Pharmaceutica, N.V. | 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors |
-
2010
- 2010-10-13 WO PCT/EP2010/065300 patent/WO2011045330A1/en not_active Ceased
- 2010-10-13 EA EA201270540A patent/EA019558B1/ru not_active IP Right Cessation
- 2010-10-13 US US13/395,891 patent/US8497270B2/en active Active
- 2010-10-13 ES ES10772998.0T patent/ES2446720T3/es active Active
- 2010-10-13 BR BR112012008586A patent/BR112012008586A2/pt not_active IP Right Cessation
- 2010-10-13 JP JP2012533614A patent/JP5624148B2/ja active Active
- 2010-10-13 NZ NZ598766A patent/NZ598766A/xx not_active IP Right Cessation
- 2010-10-13 EP EP10772998.0A patent/EP2488521B1/en active Active
- 2010-10-13 MX MX2012004426A patent/MX2012004426A/es active IP Right Grant
- 2010-10-13 KR KR1020127009345A patent/KR20120087916A/ko not_active Abandoned
- 2010-10-13 AU AU2010305805A patent/AU2010305805B2/en active Active
- 2010-10-13 CA CA2777664A patent/CA2777664C/en active Active
- 2010-10-13 CN CN201080046163.3A patent/CN102574854B/zh active Active
-
2012
- 2012-03-26 IL IL218845A patent/IL218845A0/en unknown
- 2012-04-05 ZA ZA2012/02516A patent/ZA201202516B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA019558B1 (ru) | 2014-04-30 |
| BR112012008586A2 (pt) | 2016-11-29 |
| US8497270B2 (en) | 2013-07-30 |
| NZ598766A (en) | 2013-09-27 |
| AU2010305805B2 (en) | 2014-04-03 |
| AU2010305805A1 (en) | 2012-04-19 |
| JP5624148B2 (ja) | 2014-11-12 |
| EA201270540A1 (ru) | 2012-09-28 |
| CN102574854B (zh) | 2014-04-16 |
| KR20120087916A (ko) | 2012-08-07 |
| ZA201202516B (en) | 2013-09-25 |
| WO2011045330A1 (en) | 2011-04-21 |
| US20120172367A1 (en) | 2012-07-05 |
| CN102574854A (zh) | 2012-07-11 |
| CA2777664A1 (en) | 2011-04-21 |
| MX2012004426A (es) | 2012-07-30 |
| IL218845A0 (en) | 2012-06-28 |
| EP2488521A1 (en) | 2012-08-22 |
| JP2013507423A (ja) | 2013-03-04 |
| ES2446720T3 (es) | 2014-03-10 |
| EP2488521B1 (en) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2777664C (en) | Macrocyclic integrase inhibitors | |
| JP5739517B2 (ja) | 大環状インテグラーゼ阻害剤 | |
| AU2012352110B2 (en) | Derivatives of betulin | |
| WO2021057832A1 (en) | Kras mutant protein inhibitor | |
| BRPI0720858A2 (pt) | Pirimidinas 6-substituídas inibidoras de hiv | |
| AU2016381072B2 (en) | Fused Tricyclic Heterocyclic compounds as HIV integrase inhibitors | |
| TWI454476B (zh) | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 | |
| AU2017367714B2 (en) | Tricyclic heterocycle compounds useful as HIV integrase inhibitors | |
| WO2012112345A1 (en) | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | |
| HK1172012A (en) | Macrocyclic integrase inhibitors | |
| HK1172012B (en) | Macrocyclic integrase inhibitors | |
| AU2012218004A1 (en) | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |